AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
-$0.02 today
- Market cap
- $3.60B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
Volume 2.58M
Average 6.37M
ABCL Long-term Investments
Investments the company intends to hold for more than a year.
AbCellera Biologics Inc.NASDAQ: ABCL
Long-term Investments · Q3 FY2026 · quarter ended Sep 2026
Long-term investments falls 31.6% from a year ago
Long-term investments stood at $63.85M at the end of Q3 FY2026, down 31.6% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.
Context
- Long-term investments amounted to 4.3% of total assets at the end of Q3 FY2026, down 2.6 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term investments keeps falling in the next quarterly balance sheet after a -31.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 62.58M USD
- Year-over-year change
- -24.0%
- 4-year CAGR
- +5.6%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.58M | -24.0% |
| FY2024 | 2024-12-31 | 82.3M | +24.8% |
| FY2023 | 2023-12-31 | 65.94M | -9.1% |
| FY2022 | 2022-12-31 | 72.52M | +44.1% |
| FY2021 | 2021-12-31 | 50.31M | — |
Long-term Investments vs competitors
How ABCL compares with its peers on the latest reported figures
- ABCL's Sep 2026 long-term investments of $63.85M is the highest of the 4 companies compared; the peer median is $1.06M.
- Its year-over-year change of -31.6% is the highest of 2, against a peer median of -54.0%.
- Long-term investments amounts to 4.3% of total assets for ABCL, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $63.85M | -31.6% | -4.8% | 4.3% | |
| Mar 2026 | $14.7M | -54.0% | -48.7% | 1.4% | |
| Mar 2026 | $1.06M | — | — | 0.5% | |
GENBGenerate Biomedicines, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ABCL) | $1.06M | -54.0% | -48.7% | 0.5% | |
Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 476.14M | 386.54M | 133.32M | 156.33M | 128.51M |
| Short-term Investments | 246.84M | 499.95M | 627.27M | 469.29M | 405.31M |
| Net Receivables | 174.86M | 103.41M | 64.38M | 92.13M | 153.4M |
| Inventory | 1.67M | 1.53M | 1.11M | 0 | 6.34M |
| Other Current Assets | 25M | 25M | 45.91M | 33.63M | 34.67M |
| Total Current Assets | 929.8M | 1.03B | 871.99M | 751.37M | 728.23M |
| Property, Plant & Equipment (Net) | 111.62M | 217.26M | 287.7M | 340.43M | 428M |
| Goodwill | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M |
| Intangible Assets | 148.39M | 131.5M | 120.43M | 42.11M | 38.38M |
| Long-term Investments | 50.31M | 72.52M | 65.94M | 82.3M | 62.58M |
| Tax Assets | 7.41M | 5.3M | 0 | 0 | 0 |
| Other Non-current Assets | 23.23M | 41.03M | 94.24M | 96.54M | 51.95M |
| Total Non-current Assets | 388.77M | 515.42M | 616.11M | 609.18M | 628.72M |
| Total Assets | 1.32B | 1.54B | 1.49B | 1.36B | 1.36B |
| Account Payables | 14.92M | 14.83M | 25.51M | 34.35M | 25.23M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 35.68M | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.54M | 21.61M | 18.96M | 21.18M | 22.51M |
| Other Current Liabilities | 54.85M | 69.84M | 60.68M | 8.09M | 0 |
| Total Current Liabilities | 120.68M | 118.32M | 119.01M | 76.61M | 64.31M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 37.37M | 33.18M | 30.61M | 10.05M | 9.12M |
| Deferred Revenue (Non-current) | 60.76M | 60.32M | 104.11M | 155.59M | 174.45M |
| Other Non-current Liabilities | 37.62M | 19.14M | 10.82M | 1.47M | 4.77M |
| Total Non-current Liabilities | 172.16M | 189.31M | 216.76M | 227.86M | 325.74M |
| Total Liabilities | 292.84M | 307.63M | 335.78M | 304.47M | 390.05M |
| Common Stock | 722.43M | 734.37M | 753.2M | 777.17M | 802.34M |
| Retained Earnings | 267.67M | 426.19M | 279.79M | 116.93M | (29.48M) |
| Accumulated OCI | 280K | (1.39M) | (1.72M) | (4.38M) | (4.23M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.03B | 1.23B | 1.15B | 1.06B | 966.9M |
| Total Debt | 40.07M | 82.26M | 77.38M | 65.36M | 143.22M |
| Net Debt | (436.08M) | (304.28M) | (55.94M) | (90.96M) | 14.71M |
AbCellera Biologics Inc.
NASDAQ:ABCL
Intrinsic Alpha fair value
Locked
Current Price
$11.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.